These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 30651028)
1. Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors. Lee J; Graham A; Sion A J Oncol Pharm Pract; 2019 Dec; 25(8):1867-1872. PubMed ID: 30651028 [TBL] [Abstract][Full Text] [Related]
2. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies. Ali AK; Watson DE Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039 [TBL] [Abstract][Full Text] [Related]
3. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807 [TBL] [Abstract][Full Text] [Related]
4. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Reynolds KL; Guidon AC Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825 [TBL] [Abstract][Full Text] [Related]
5. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Barbee MS; Ogunniyi A; Horvat TZ; Dang TO Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832 [TBL] [Abstract][Full Text] [Related]
6. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Weber JS; Postow M; Lao CD; Schadendorf D Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894 [TBL] [Abstract][Full Text] [Related]
13. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. Abdel-Wahab N; Shah M; Suarez-Almazor ME PLoS One; 2016; 11(7):e0160221. PubMed ID: 27472273 [TBL] [Abstract][Full Text] [Related]
14. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Cappelli LC; Gutierrez AK; Baer AN; Albayda J; Manno RL; Haque U; Lipson EJ; Bleich KB; Shah AA; Naidoo J; Brahmer JR; Le D; Bingham CO Ann Rheum Dis; 2017 Jan; 76(1):43-50. PubMed ID: 27307501 [TBL] [Abstract][Full Text] [Related]
15. Medication use evaluation of programmed death-1 inhibitors in a veteran population. Nguyen V; Huq M J Oncol Pharm Pract; 2019 Jul; 25(5):1066-1075. PubMed ID: 29726785 [TBL] [Abstract][Full Text] [Related]
16. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387 [TBL] [Abstract][Full Text] [Related]
17. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Hasegawa S; Ikesue H; Nakao S; Shimada K; Mukai R; Tanaka M; Matsumoto K; Inoue M; Satake R; Yoshida Y; Goto F; Hashida T; Nakamura M Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1279-1294. PubMed ID: 32869941 [TBL] [Abstract][Full Text] [Related]
18. [Management of Toxicities of Immune Checkpoint Inhibitors]. Horio Y Gan To Kagaku Ryoho; 2017 Mar; 44(3):185-190. PubMed ID: 28292987 [TBL] [Abstract][Full Text] [Related]
19. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630 [TBL] [Abstract][Full Text] [Related]
20. [Efficacy and Management of Adverse Events of Ipilimumab Including Combination Therapy with Nivolumab]. Uhara H; Itakura E Gan To Kagaku Ryoho; 2019 Jun; 46(6):1017-1026. PubMed ID: 31273168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]